0 false false false false false false false false false false true false false false false false false No description of principal activity 2024-11-01 Sage Accounts Production Advanced 2025 - FRS102_2025 800 800 xbrli:pure xbrli:shares iso4217:GBP 04091168 2024-11-01 2025-10-31 04091168 2025-10-31 04091168 2024-10-31 04091168 2023-11-01 2024-10-31 04091168 2024-10-31 04091168 2023-10-31 04091168 core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2024-11-01 2025-10-31 04091168 bus:Director1 2024-11-01 2025-10-31 04091168 core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2025-10-31 04091168 core:WithinOneYear 2025-10-31 04091168 core:WithinOneYear 2024-10-31 04091168 core:AfterOneYear 2025-10-31 04091168 core:AfterOneYear 2024-10-31 04091168 core:ShareCapital 2025-10-31 04091168 core:ShareCapital 2024-10-31 04091168 core:RetainedEarningsAccumulatedLosses 2025-10-31 04091168 core:RetainedEarningsAccumulatedLosses 2024-10-31 04091168 bus:SmallEntities 2024-11-01 2025-10-31 04091168 bus:AuditExempt-NoAccountantsReport 2024-11-01 2025-10-31 04091168 bus:SmallCompaniesRegimeForAccounts 2024-11-01 2025-10-31 04091168 bus:PrivateLimitedCompanyLtd 2024-11-01 2025-10-31 04091168 bus:FullAccounts 2024-11-01 2025-10-31
COMPANY REGISTRATION NUMBER: 04091168
London Healthcare Ltd
Filleted Unaudited Financial Statements
31 October 2025
London Healthcare Ltd
Statement of Financial Position
31 October 2025
2025
2024
Note
£
£
£
Current assets
Debtors
5
172
32
Cash at bank and in hand
2,857
2,857
-------
-------
3,029
2,889
Creditors: amounts falling due within one year
6
11,841
10,967
--------
--------
Net current liabilities
8,812
8,078
-------
-------
Total assets less current liabilities
( 8,812)
( 8,078)
Creditors: amounts falling due after more than one year
7
10,000
10,000
--------
--------
Net liabilities
( 18,812)
( 18,078)
--------
--------
Capital and reserves
Called up share capital
2
2
Profit and loss account
( 18,814)
( 18,080)
--------
--------
Shareholders deficit
( 18,812)
( 18,078)
--------
--------
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
In accordance with section 444 of the Companies Act 2006, the statement of income and retained earnings has not been delivered.
For the year ending 31 October 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Director's responsibilities:
- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476 ;
- The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements .
London Healthcare Ltd
Statement of Financial Position (continued)
31 October 2025
These financial statements were approved by the board of directors and authorised for issue on 14 July 2026 , and are signed on behalf of the board by:
Mr M Taha
Director
Company registration number: 04091168
London Healthcare Ltd
Notes to the Financial Statements
Year ended 31 October 2025
1. General information
The company is a private company limited by shares, registered in England and Wales. The address of the registered office is Princes of Wales House, 18/19 Salmon Fields Business Village, Royton, Oldham, OL2 6HT.
2. Statement of compliance
These financial statements have been prepared in compliance with Section 1A of FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'.
3. Accounting policies
Basis of preparation
The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.
The financial statements are prepared in sterling, which is the functional currency of the entity.
Intangible assets
Intangible assets are initially recorded at cost, and are subsequently stated at cost less any accumulated amortisation and impairment losses. Any intangible assets carried at revalued amounts, are recorded at the fair value at the date of revaluation, as determined by reference to an active market, less any subsequent accumulated amortisation and subsequent accumulated impairment losses. Intangible assets acquired as part of a business combination are only recognised separately from goodwill when they arise from contractual or other legal rights, are separable, the expected future economic benefits are probable and the cost or value can be measured reliably.
Amortisation
Amortisation is calculated so as to write off the cost of an asset, less its estimated residual value, over the useful life of that asset as follows:
Trademarks
-
100% straight line
If there is an indication that there has been a significant change in amortisation rate, useful life or residual value of an intangible asset, the amortisation is revised prospectively to reflect the new estimates.
Impairment of fixed assets
A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date. For the purposes of impairment testing, when it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs. The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that largely independent of the cash inflows from other assets or groups of assets. For impairment testing of goodwill, the goodwill acquired in a business combination is, from the acquisition date, allocated to each of the cash-generating units that are expected to benefit from the synergies of the combination, irrespective of whether other assets or liabilities of the company are assigned to those units.
Financial instruments
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the entity after deducting all of its financial liabilities. Where the contractual obligations of financial instruments (including share capital) are equivalent to a similar debt instrument, those financial instruments are classed as financial liabilities. Financial liabilities are presented as such in the balance sheet. Finance costs and gains or losses relating to financial liabilities are included in the profit and loss account. Finance costs are calculated so as to produce a constant rate of return on the outstanding liability. Where the contractual terms of share capital do not have any terms meeting the definition of a financial liability then this is classed as an equity instrument. Dividends and distributions relating to equity instruments are debited direct to equity.
4. Intangible assets
Development costs
£
Cost
At 1 November 2024 and 31 October 2025
800
----
Amortisation
At 1 November 2024 and 31 October 2025
800
----
Carrying amount
At 31 October 2025
----
At 31 October 2024
----
5. Debtors
2025
2024
£
£
Other debtors
172
32
----
----
6. Creditors: amounts falling due within one year
2025
2024
£
£
Trade creditors
1,068
194
Other creditors
10,773
10,773
--------
--------
11,841
10,967
--------
--------
7. Creditors: amounts falling due after more than one year
2025
2024
£
£
Other creditors
10,000
10,000
--------
--------
8. Director's advances, credits and guarantees
Included within creditors due within one year are loans from directors totalling £10,173 (2024: £10,173) on which no interest is being charged. The loans are repayable in full or in part on demand.
9. Related party transactions
The company was under the control of Mr M Taha throughout the current and previous year. Mr M Taha is the managing director and majority shareholder. No transactions with related parties were undertaken such as are required to be disclosed under Financial Reporting Standard 8.